☆ 4.7 Review

Cisplatin in Liver Cancer Therapy

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review Oncology

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

Gael S. Roth et al.

Summary: Cholangiocarcinoma is a deadly cancer with limited treatment options. Recent advances in immunotherapy have shown improved survival in the first-line treatment of advanced cholangiocarcinoma. Molecular profiling has identified targetable alterations, opening the way to personalized medicine. This review discusses recent clinical trial findings and the importance of systematic molecular screening for personalized treatment.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹
Article Multidisciplinary Sciences

Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation

Ahmed W. Moawad et al.

Summary: Hepatocellular carcinoma (HCC), the most common primary liver neoplasm, has seen its incidence double over the past two decades. Despite surveillance, most HCC cases are diagnosed at advanced stages and can only be treated with transarterial chemo-embolization (TACE) or systemic therapy. TACE failure is common, occurring in up to 60% of cases, leading to financial and emotional burden for patients. Radiomics has emerged as a new tool to predict tumor response to TACE using pre-procedural CT studies.

SCIENTIFIC DATA (2023)

添加到收藏夹
Review Oncology

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma

Carmelo Laface et al.

Summary: One of the most important abilities of a tumor is to establish immunosuppression inside the tumor microenvironment. This is achieved through various mechanisms of tumor immune escape identified in experimental studies. In the liver, the microenvironment is oriented towards immune tolerance, preventing autoimmune reactions. Additionally, hepatocellular carcinoma often develops in the context of chronic inflammation. Due to these factors, different immunotherapeutic strategies have been developed and evaluated for advanced HCC. This review provides an overview of the clinical applications of immunotherapy for advanced HCC, including approved drugs and ongoing clinical trials.

CANCERS (2023)

添加到收藏夹
Review Pharmacology & Pharmacy

State of the art and perspectives in pediatric hepatocellular carcinoma

Graziana Digiacomo et al.

Summary: Hepatoblastoma and pediatric hepatocellular carcinoma are rare primary malignant liver cancers in children and young adults. Hepatoblastoma is the most common type, accounting for about 70% of cases, while pediatric hepatocellular carcinoma is uncommon and has a poor prognosis. Surgery is the best option for cure, but chemotherapy can be used as an additional treatment. Studies are being conducted to identify genetic profiles and potential targets for treatment.

BIOCHEMICAL PHARMACOLOGY (2023)

添加到收藏夹
Article Oncology

Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma

Dong-yang Ding et al.

Summary: In this study, thrombospondin-1 (TSP1) was found to predict gemcitabine chemosensitivity in intrahepatic cholangiocarcinoma (ICC) patients and enhance the efficacy of gemcitabine chemotherapy. This finding is of great significance for improving the sensitivity of ICC patients to gemcitabine chemotherapy.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹
Review Biochemistry & Molecular Biology

Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review

Beata Szefler et al.

Summary: Pt (II) derivatives interact with nucleobases of DNA, leading to anti-cancer activity through spontaneous and non-spontaneous reactions. The formed mono- and diaqua products further complex with guanine or adenine, triggering processes that result in cancer cell death. The interactions can also occur with other chemical compounds, as shown by theoretical and experimental studies on B vitamins and Pt (II) derivatives. The strength of the interactions varies, with carboplatin products exhibiting the weakest interaction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹
Article Oncology

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis

Takanori Miyoshi et al.

Summary: This study found no significant difference in the preventive effect against CDDP-induced nephrotoxicity between 20 mEq and 8 mEq Mg supplementation in cancer patients receiving CDDP-based chemotherapy. Cardiac disease and albumin levels were identified as independent risk factors for CDDP-induced nephrotoxicity.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹
Review Oncology

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Yongkun Sun et al.

Summary: Hepatocellular carcinoma (HCC) is a common type of liver cancer that causes many cancer-related deaths worldwide. Though a molecular targeted drug has been available for the treatment of advanced HCC, no Chinese guidelines for novel molecular targeted therapies have been established. An interdisciplinary panel has reviewed the treatment of advanced HCC and provided an overview of molecular targeted therapies for healthcare professionals.

LIVER CANCER (2022)

添加到收藏夹
Article Oncology

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

Masatoshi Kudo et al.

Summary: The final OS analysis from the TACTICS trial demonstrated no significant OS benefit of TACE plus sorafenib compared to TACE alone in patients with HCC. However, there was a clinically meaningful OS prolongation and significantly improved PFS. Therefore, TACE plus sorafenib can be considered as a treatment option for intermediate-stage HCC, especially in patients with high tumor burden.

LIVER CANCER (2022)

添加到收藏夹
Article Oncology

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

Hidekatsu Kuroda et al.

Summary: This study compared the efficacy and safety of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy to LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC). The results showed that the LEN-TACE group had significantly higher overall survival (OS) and progression-free survival (PFS) compared to the LEN monotherapy group. The initial response to LEN treatment was identified as an independent factor contributing to the deep response in LEN-TACE sequential therapy.

LIVER CANCER (2022)

添加到收藏夹
Article Oncology

The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion

Masaki Kaibori et al.

Summary: The study demonstrates that sorafenib and intermittent hepatic arterial infusion chemotherapy with cisplatin have favorable efficacy and acceptable safety for patients with unresectable hepatocellular carcinoma (HCC) with severe portal vein invasion, making it a feasible treatment option.

CANCER INVESTIGATION (2022)

添加到收藏夹
Article Oncology

Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells

Sae Hamaya et al.

Summary: The aim of this study was to explore the mechanism of lenvatinib resistance and investigate potential drugs that may improve the treatment of lenvatinib-resistant cells. The proliferative potential of lenvatinib-resistant cells was enhanced by activation of the ERK signaling pathway and changes in miRNAs. Cisplatin exhibited antitumor effects in lenvatinib-resistant cells and triggered the DNA damage response through the ATM/ATR-Chk1/Chk2 signaling pathway.

ANTICANCER RESEARCH (2022)

添加到收藏夹
Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Article Chemistry, Medicinal

Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma

Qiao Yang et al.

Summary: This study explored the efficacy and safety of gemcitabine combined with cisplatin in the treatment of recurrent/metastatic nasopharyngeal carcinoma. The results showed that this combination therapy had significant advantages in terms of therapeutic efficacy, survival rate, and quality of life for patients.

DRUG DESIGN DEVELOPMENT AND THERAPY (2022)

添加到收藏夹
Review Oncology

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

Nawar Al Nasrallah et al.

Summary: XPC is not only important in skin cancer, but also plays a protective role in non-dermatologic cancers. In addition to its involvement in GG-NER, XPC also participates in other DNA repair pathways, DNA damage response, and transcriptional regulation. XPC expression levels and polymorphisms may impact development and could serve as predictive and therapeutic biomarkers for non-dermatologic cancers.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Do-Youn Oh et al.

Summary: In patients with advanced biliary tract cancer, gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety, with an objective response rate of 66%. The most common adverse events were hematological, with no unexpected safety events observed.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹
Review Chemistry, Medicinal

The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022

Shihao Su et al.

Summary: This article provides an overview of the development and research direction of platinum-based antitumor drugs, including the role of platinum prodrugs and the anticancer immune response in tumor therapy. The article identifies main challenges in platinum drug research and proposes potential strategies to overcome these challenges from a drug design perspective.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹
Review Biochemistry & Molecular Biology

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin

Maria Konoshenko et al.

Summary: This review summarizes and analyzes the data on miRNAs associated with lung cancer cisplatin chemotherapy response, and identifies 12 miRNAs with high predictive potential. The study contributes to predicting lung cancer cisplatin sensitivity or resistance, as well as the development of more effective cisplatin combination therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Review Biochemistry & Molecular Biology

Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted

Reem Ali et al.

Summary: Cisplatin is one of the oldest chemotherapeutic agents and has been used to treat various types of cancer. However, tumor cells often develop resistance mechanisms, limiting the effectiveness of cisplatin treatment. Extensive molecular and genetic profiling of patients is needed to identify individuals who can benefit from cisplatin therapy, and combining it with targeted therapies may improve treatment outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Current epidemiology of cholangiocarcinoma in Western countries

Mathew Vithayathil et al.

Summary: Cholangiocarcinomas are cancers that originate from the bile ducts and can occur within or outside the liver. In Western countries, the death rate due to intrahepatic cancers is rising at a higher rate than that of extrahepatic cancers, possibly due to an increase in cases of liver disease and misclassification of cancer types.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹
Article Oncology

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

Sunisa Prasopporn et al.

Summary: This study found that the combination therapy of the SMAC mimetic LCL161 with GEM/CIS can inhibit and prevent multidrug resistance in cholangiocarcinoma (CCA), restoring sensitivity to the treatment. The activation of cIAP2 allows CCA to escape GEM/CIS, but the suppression of cIAP2 reestablishes the apoptotic profile of CCA, making it vulnerable to GEM/CIS.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹
Review Oncology

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Weiwei Li et al.

Summary: Conversion therapy shows potential effectiveness for initially unresectable hepatocellular carcinoma patients. The combination therapy of TACE with TKIs and ICIs has higher conversion rates and better tumor response compared to other treatments. Surgical resection after successful conversion therapy improves patient survival.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹
Article Oncology

YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation

Chen-Song Huang et al.

Summary: YTHDF2 was found to be upregulated in ICC tissues, especially in chemoresistant ICC tissues, and correlated with poor prognosis. Silencing YTHDF2 inhibited proliferation, promoted apoptosis, and induced G0/G1 cell cycle arrest. Downregulation of YTHDF2 also increased DNA damage and sensitized ICC cells to cisplatin. YTHDF2 overexpression had the opposite effects. Integration analysis revealed that YTHDF2 played a role in tumorigenesis and cisplatin resistance by promoting the degradation of CDKN1B mRNA in an m(6)A-dependent manner. Downregulation of CDKN1B enhanced the effects of YTHDF2 silencing on tumorigenesis and cisplatin response. Furthermore, the combination treatment of YTHDF2 siRNA and cisplatin significantly enhanced the anti-tumor effect of cisplatin in a chemoresistant ICC PDX model.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

添加到收藏夹
Review Cardiac & Cardiovascular Systems

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)

Thierry de Baere et al.

Summary: Several publications and recommendations have highlighted the benefits of superselective conventional TransArterial ChemoEmbolization (cTACE) in treating Hepatocellular Carcinoma (HCC). The use of a microcatheter positioned close to the tumor improves outcomes and minimizes collateral damage to the liver parenchyma. Experts recommend that cTACE should be superselective and performed with a 1.5-2.0 Fr microcatheter. Angio Cone-Beam Computed Tomography (CBCT) can be used to guide the procedure and assess tumor coverage.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2022)

添加到收藏夹
Review Medicine, General & Internal

Hepatocellular carcinoma

Arndt Vogel et al.

Summary: Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.

LANCET (2022)

添加到收藏夹
Review Oncology

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities

Carmelo Laface et al.

Summary: Hepatocellular carcinoma is the most common primary liver cancer with poor prognosis. New molecular targeted therapies have shown promising results in recent years. However, research into new treatments is still necessary.

CANCERS (2022)

添加到收藏夹
Review Oncology

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review

Liwei Sun et al.

Summary: Lenvatinib plus TACE therapy is a favorable treatment option for patients with hepatocellular carcinoma, particularly for those who are not suitable for TACE. It has shown superior efficacy compared to monotherapy with Lenvatinib or other therapies.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹
Review Biochemistry & Molecular Biology

Cisplatin Resistance: Genetic and Epigenetic Factors Involved

Yuliannis Lugones et al.

Summary: Cisplatin is a widely used anti-cancer drug, but tumor cells can develop resistance to its damaging effects through genetic and epigenetic changes, as well as other resistance mechanisms.

BIOMOLECULES (2022)

添加到收藏夹
Review Multidisciplinary Sciences

Cisplatin for cancer therapy and overcoming chemoresistance

Ranmali Ranasinghe et al.

Summary: Cisplatin is a leading chemotherapy drug for cancer treatment, but its acute toxicity remains a major challenge. While efforts are ongoing to discover more effective drugs, nothing has surpassed the benefits of cisplatin so far. Oxaliplatin is considered superior in colorectal cancer, but cisplatin still has a wide application in treating gynaecological cancers.

HELIYON (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma

Oyunjargal Baterdene et al.

Summary: A 60-year-old woman with unresectable HCCs developed hyperprogressive disease (HPD) after atezolizumab and bevacizumab (ATZ + BEV) treatment, but was able to resume and continue ATZ + BEV after salvage therapy with drug-eluting bead (DEB)-TACE.

CLINICAL JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹
Review Pharmacology & Pharmacy

Cisplatin in cancer treatment

Andrea M. P. Romani

Summary: Cisplatin is a commonly used chemotherapy agent that inhibits the growth of cancer cells by interfering with their DNA repair mechanism. However, its usage is limited due to significant side effects. Recent research has focused on combining cisplatin with other anti-cancer drugs and exploring its immunomodulatory effects.

BIOCHEMICAL PHARMACOLOGY (2022)

添加到收藏夹
Article Oncology

The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial

Panot Sainamthip et al.

Summary: This study aimed to evaluate the efficacy of mannitol combined hydration in preventing cisplatin-induced nephrotoxicity. 48 patients with solid cancers treated with cisplatin were randomly assigned to receive mannitol or placebo. The results showed that mannitol combined hydration significantly reduced renal damage, especially in patients receiving high-dose cisplatin or concurrent radiation.

JCO GLOBAL ONCOLOGY (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma

Xiyang Wei et al.

Summary: miR-125b loss activates the HIF1 alpha/pAKT loop, contributing to HCC resistance to TACE. Key nodes in this axis hold the potential in assisting patients with HCC to choose TACE therapy.

HEPATOLOGY (2021)

添加到收藏夹
Review Oncology

Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature

Kyoko Oura et al.

Summary: For patients with unresectable advanced hepatocellular carcinoma, formulating sequential therapeutic strategies based on pathological conditions using molecular targeted agents and transcatheter arterial chemoembolization can be effective. In one case, sequential therapy with MTAs and TACE showed significant efficacy, indicating the importance of multidisciplinary treatment strategies for advanced HCC.

MOLECULAR AND CLINICAL ONCOLOGY (2021)

添加到收藏夹
Review Oncology

Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?

Antonio Ruggiero et al.

Summary: The study emphasized the importance of understanding the renal toxic effects of cisplatin in children and the controversial use of diuretics for nephroprotection, given the lack of guidelines and inconclusive data on their utility.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

添加到收藏夹
Article Cell Biology

Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma

Ahmed Montasser et al.

Summary: This study evaluated the impact of transarterial chemoembolization (TACE) on programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in surgically treated hepatocellular carcinomas (HCCs). The results showed that TACE treatment led to increased levels of PD-1 and PD-L1 expression in HCCs, supporting the potential use of TACE in combination with immunotherapy to enhance tumor response in selected cases.

HISTOPATHOLOGY (2021)

添加到收藏夹
Review Chemistry, Multidisciplinary

Natural products: potential treatments for cisplatin-induced nephrotoxicity

Chun-yan Fang et al.

Summary: Cisplatin is a clinically advanced anticancer drug, but its severe nephrotoxic effects limit its clinical use. There are currently no effective drugs for cisplatin-induced kidney injury, but natural products may have potential therapeutic effects.

ACTA PHARMACOLOGICA SINICA (2021)

添加到收藏夹
Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

Aditi Jain et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. This review discusses the molecular mechanisms involved in therapy resistance in PDAC, current approaches in targeting these mechanisms, lessons learned from the failure of immunotherapy in PDAC, and ongoing efforts to improve tumor's immunological response.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹
Article Oncology

Hsa-circRNA-G004213 promotes cisplatin sensitivity by regulating miR-513b-5p/PRPF39 in liver cancer

Ling Qin et al.

Summary: This study revealed the association between circ-G004213 and the prognosis of liver cancer patients following TACE, suggesting its potential as an indicator for predicting the efficacy of TACE.

MOLECULAR MEDICINE REPORTS (2021)

添加到收藏夹
Article Cell Biology

HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma

Zhan-Sheng Zhang et al.

Summary: The study found that the activation of the HGF/c-Met axis induces the activation of the PI3K/Akt and MEK/ERK signaling pathways, contributing to cisplatin-mediated PD-L1 expression. These findings may provide a new avenue for the treatment of HCC.

CELL BIOLOGY INTERNATIONAL (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment

Robert Csaba Kiss et al.

Summary: Platinum-based chemotherapies, such as cisplatin, are vital in cancer treatment, but the development of resistance and toxicity pose challenges. Understanding DNA repair pathways and biomarkers for cisplatin resistance can help improve patient stratification and treatment personalization. Current treatments and future strategies are being explored to overcome cisplatin resistance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹
Review Oncology

Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art

Carmelo Laface et al.

Summary: Liver functional failure contributes significantly to cancer-related mortality. Systemic chemotherapy offers modest benefits for disease control and survival, but with notable adverse effects. Liver malignancies are mostly perfused by the hepatic artery, leading to the strategy of hepatic arterial infusion of chemotherapy. Current studies show favorable safety and efficacy outcomes for this approach in advanced hepatobiliary cancers, warranting further large-scale studies for confirmation.

CANCERS (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Glutathione-coordinated metal complexes as substrates for cellular transporters

Stephen A. Pearson et al.

Summary: Glutathione plays important roles in both prokaryotes and eukaryotes, including detoxification of metals and transportation of iron-sulfur clusters. Different ABC transporters have similar functions in different organisms, indicating common evolutionary features in these processes.

METALLOMICS (2021)

添加到收藏夹
Review Oncology

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC

Alessandro Granito et al.

Summary: Regorafenib has shown significant efficacy in the treatment of HCC, inhibiting tumor growth and spread while also positively impacting immunomodulation. Studies have confirmed its effectiveness as a second-line treatment after sorafenib failure.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

添加到收藏夹
Review Pharmacology & Pharmacy

Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity

Alfredo G. Casanova et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)

添加到收藏夹
Article Oncology

International trends in hepatocellular carcinoma incidence, 1978-2012

Jessica L. Petrick et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹
Review Medicine, Research & Experimental

circRNAs and Exosomes: A Mysterious Frontier for Human Cancer

Xuefei Shi et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2020)

添加到收藏夹
Review Food Science & Technology

Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents

Neife Aparecida Guinaim dos Santos et al.

FOOD AND CHEMICAL TOXICOLOGY (2020)

添加到收藏夹
Review Oncology

Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer

Alberto Romano et al.

CANCERS (2020)

添加到收藏夹
Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Oncology

Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study

Tetsunari Hase et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹
Review Medicine, General & Internal

Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma A meta-analysis

Guan-Bao Long et al.

MEDICINE (2020)

添加到收藏夹
Article Cell Biology

Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1

Shenghao Li et al.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹
Review Pediatrics

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

David R. Freyer et al.

LANCET CHILD & ADOLESCENT HEALTH (2020)

添加到收藏夹
Review Biochemistry & Molecular Biology

Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

Renata Zajaczkowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹
Review Biochemistry & Molecular Biology

Cisplatin: The first metal based anticancer drug

Sumit Ghosh

BIOORGANIC CHEMISTRY (2019)

添加到收藏夹
Article Medicine, General & Internal

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Yuan Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹
Article Oncology

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

Masaaki Kondo et al.

BMC CANCER (2019)

添加到收藏夹
Article Oncology

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Ludovic Fournel et al.

CANCER LETTERS (2019)

添加到收藏夹
Article Medicine, Research & Experimental

Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule

Fei Deng et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹
Article Medical Laboratory Technology

Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization

Hamdy E. A. Ali et al.

CLINICAL BIOCHEMISTRY (2019)

添加到收藏夹
Article Gastroenterology & Hepatology

Non-alcoholic fatty liver disease - A global public health perspective

Zobair M. Younossi

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹
Review Oncology

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Eva Clemens et al.

LANCET ONCOLOGY (2019)

添加到收藏夹
Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

添加到收藏夹
Review Cell Biology

Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity

Vladislav Volarevic et al.

JOURNAL OF BIOMEDICAL SCIENCE (2019)

添加到收藏夹
Review Oncology

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy

Tomaz Makovec

RADIOLOGY AND ONCOLOGY (2019)

添加到收藏夹
Article Oncology

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

Masahiro Hatooka et al.

BMC CANCER (2018)

添加到收藏夹
Article Oncology

Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis

Jong Hwan Choi et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

添加到收藏夹
Article Pharmacology & Pharmacy

Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity

Tom T. G. Nieskens et al.

DRUG METABOLISM AND DISPOSITION (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

添加到收藏夹
Article Veterinary Sciences

Intravenous rocuronium 0.3 mg/kg improves the conditions for tracheal intubation in cats: a randomized, placebo-controlled trial

Daniel M. Sakai et al.

JOURNAL OF FELINE MEDICINE AND SURGERY (2018)

添加到收藏夹
Review Medicine, Research & Experimental

Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

Iman W. Achkar et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

添加到收藏夹
Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹
Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹
Review Biochemistry & Molecular Biology

Facilitating the Cellular Accumulation of Pt-Based Chemotherapeutic Drugs

Ian Henry Lambert et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹
Review Gastroenterology & Hepatology

Pediatric hepatocellular carcinoma

Rajeev Khanna et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹
Review Medicine, Research & Experimental

Role of HIF-1 in Cancer Progression: Novel Insights. A Review

Aldo Pezzuto et al.

CURRENT MOLECULAR MEDICINE (2018)

添加到收藏夹
Review Medicine, General & Internal

Cisplatin-induced cardiotoxicity with midrange ejection fraction A case report and review of the literature

Yang Hu et al.

MEDICINE (2018)

添加到收藏夹
Article Gastroenterology & Hepatology

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata et al.

HEPATOLOGY INTERNATIONAL (2017)

添加到收藏夹
Review Gastroenterology & Hepatology

The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹
Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

添加到收藏夹
Article Oncology

Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

Rebecka L. Meyers et al.

LANCET ONCOLOGY (2017)

添加到收藏夹
Review Oncology

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

Daniel J. Crona et al.

ONCOLOGIST (2017)

添加到收藏夹
Review Biology

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

Yanqing Huang et al.

SCIENCE CHINA-LIFE SCIENCES (2017)

添加到收藏夹
Review Oncology

The molecular mechanisms of chemoresistance in cancers

Hua-Chuan Zheng

ONCOTARGET (2017)

添加到收藏夹
Article Multidisciplinary Sciences

MiR-488 inhibits proliferation and cisplatin sensibility in non-smallcell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Chao Fang et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹
Article Oncology

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

Linda Tran et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹
Review Neurosciences

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

Hana Starobova et al.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2017)

添加到收藏夹
Review Pharmacology & Pharmacy

Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review

Nicolas Kerckhove et al.

FRONTIERS IN PHARMACOLOGY (2017)

添加到收藏夹
Article Oncology

Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma

Morihiko Ishizaki et al.

CANCER INVESTIGATION (2017)

添加到收藏夹
Review Oncology

Pediatric hepatocellular carcinoma: challenges and solutions

Irene Schmid et al.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2017)

添加到收藏夹
Review Oncology

The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?

Antonio Ruggiero et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

添加到收藏夹
Article Oncology

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

Kiichiro Ninomiya et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹
Article Oncology

Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy

Trevor McKibbin et al.

SUPPORTIVE CARE IN CANCER (2016)

添加到收藏夹
Article Oncology

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

M. Ikeda et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹
Review Biochemistry & Molecular Biology

Activation of apoptosis signalling pathways by reactive oxygen species

Maureen Redza-Dutordoir et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)

添加到收藏夹
Article Biochemistry & Molecular Biology

Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells

Shuichi Kishimoto et al.

BIOMETALS (2016)

添加到收藏夹
Article Oncology

The (C)under-barhildren's (H)under-barepatic tumors (I)under-barnternational (C)under-barollaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model

Piotr Czauderna et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹
Article Oncology

Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies

Maciej Murawski et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹
Review Oncology

Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group

Johnnie K. Bass et al.

PEDIATRIC BLOOD & CANCER (2016)

添加到收藏夹
Review Oncology

Role of copper transporters in platinum resistance

Deepak Kilari et al.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹
Article Oncology

The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer

Jian Zhao et al.

BMC CANCER (2015)

添加到收藏夹
Review Oncology

Current Status of Hepatic Arterial Infusion Chemotherapy

Shuntaro Obi et al.

LIVER CANCER (2015)

添加到收藏夹
Article Oncology

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)

Masashi Kanai et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)

添加到收藏夹
Review Environmental Sciences

Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies

Angela Callejo et al.

TOXICS (2015)

添加到收藏夹
Article Physiology

Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice

Malvika H. Solanki et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)

添加到收藏夹
Article Integrative & Complementary Medicine

Thymoquinone attenuates cisplatin-induced hepatotoxicity via nuclear factor kappa- β

Abdulrahman L. Al-Malki et al.

BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2014)

添加到收藏夹
Article Oncology

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma

Atsushi Hagihara et al.

CANCER SCIENCE (2014)

添加到收藏夹
Review Pharmacology & Pharmacy

Cisplatin in cancer therapy: Molecular mechanisms of action

Shaloam Dasari et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2014)

添加到收藏夹
Article Biochemistry & Molecular Biology

Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin

Nasma D. Eljack et al.

METALLOMICS (2014)

添加到收藏夹
Article Oncology

Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases: A Report From the Children's Oncology Group

Lucie M. Turcotte et al.

PEDIATRIC BLOOD & CANCER (2014)

添加到收藏夹
Article Multidisciplinary Sciences

Association of Serum MicroRNA Expression in Hepatocellular Carcinomas Treated with Transarterial Chemoembolization and Patient Survival

Mei Liu et al.

PLOS ONE (2014)

添加到收藏夹
Article Cell Biology

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo

C. R. R. Rocha et al.

CELL DEATH & DISEASE (2014)

添加到收藏夹
Article Reproductive Biology

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer

Hiroshi Kawaguchi et al.

Journal of Ovarian Research (2014)

添加到收藏夹
Article Oncology

Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin

Akira Ouchi et al.

JOURNAL OF ONCOLOGY (2014)

添加到收藏夹
Article Physiology

Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation

Malvika H. Solanki et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)

添加到收藏夹
Article Oncology

Visualizing Inhibition of Nucleosome Mobility and Transcription by Cisplatin-DNA Interstrand Crosslinks in Live Mammalian Cells

Guangyu Zhu et al.

CANCER RESEARCH (2013)

添加到收藏夹
Article Oncology

Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)

Chigusa Morizane et al.

CANCER SCIENCE (2013)

添加到收藏夹
Article Biochemistry & Molecular Biology

The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease

Natalie K. Y. Wee et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)

添加到收藏夹
Article Oncology

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

Laura Astolfi et al.

ONCOLOGY REPORTS (2013)

添加到收藏夹
Article Multidisciplinary Sciences

Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

Rossella Marullo et al.

PLOS ONE (2013)

添加到收藏夹
Article Gastroenterology & Hepatology

Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

Kazuhiro Kasai et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

添加到收藏夹
Article Pharmacology & Pharmacy

A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells

Kristin D. Ivy et al.

MOLECULAR PHARMACOLOGY (2013)

添加到收藏夹
Review Biochemistry & Molecular Biology

Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy

Subash C. Gupta et al.

ANTIOXIDANTS & REDOX SIGNALING (2012)

添加到收藏夹
Review Pharmacology & Pharmacy

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53

Michelle Martinez-Rivera et al.

BIOCHEMICAL PHARMACOLOGY (2012)

添加到收藏夹
Review Oncology

Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy

Macus Tien Kuo et al.

CANCER RESEARCH (2012)

添加到收藏夹
Article Cardiac & Cardiovascular Systems

Transarterial Chemoembolization With Cisplatin as Second-Line Treatment for Hepatocellular Carcinoma Unresponsive to Chemoembolization With Epirubicin-Lipiodol Emulsion

Noboru Maeda et al.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2012)

添加到收藏夹
Article Biochemistry & Molecular Biology

Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells

Ganna V. Kalayda et al.

JOURNAL OF INORGANIC BIOCHEMISTRY (2012)

添加到收藏夹
Article Oncology

Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma

Irene Schmid et al.

PEDIATRIC BLOOD & CANCER (2012)

添加到收藏夹
Review Pharmacology & Pharmacy

Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes

Ding-Wu Shen et al.

PHARMACOLOGICAL REVIEWS (2012)

添加到收藏夹
Article Oncology

Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic

Armelle Lavole et al.

BULLETIN DU CANCER (2012)

添加到收藏夹
Article Oncology

A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma

Hiraku Yodono et al.

ANTI-CANCER DRUGS (2011)

添加到收藏夹
Article Oncology

Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma

Beom Kyung Kim et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)

添加到收藏夹
Article Medicine, Research & Experimental

Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization

Ming-Yen Hsieh et al.

KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2011)

添加到收藏夹
Article Oncology

Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy

Ashutosh Shrivastava et al.

MOLECULAR CANCER THERAPEUTICS (2011)

添加到收藏夹
Article Oncology

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

Ana-Maria Florea et al.

Cancers (2011)

添加到收藏夹
Review Oncology

DNA interstrand crosslink repair and cancer

Andrew J. Deans et al.

NATURE REVIEWS CANCER (2011)

添加到收藏夹
Article Oncology

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

T. Okusaka et al.

BRITISH JOURNAL OF CANCER (2010)

添加到收藏夹
Article Biochemistry & Molecular Biology

Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics

Ryan C. Todd et al.

CHEMISTRY & BIOLOGY (2010)

添加到收藏夹
Article Pediatrics

Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group

Satkiran Grewal et al.

PEDIATRICS (2010)

添加到收藏夹
Review Food Science & Technology

Mechanisms of Cisplatin Nephrotoxicity

Ronald P. Miller et al.

TOXINS (2010)

添加到收藏夹
Review Biochemistry & Molecular Biology

Cellular Responses to Cisplatin-Induced DNA Damage

Alakananda Basu et al.

JOURNAL OF NUCLEIC ACIDS (2010)

添加到收藏夹
Article Oncology

Persistent neuropathy after treatment with cisplatin and oxaliplatin

Elke E. M. Brouwers et al.

ACTA ONCOLOGICA (2009)

添加到收藏夹
Article Oncology

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

J. W. Valle et al.

BRITISH JOURNAL OF CANCER (2009)

添加到收藏夹
Article Urology & Nephrology

Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats

Koji Yokoo et al.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2009)

添加到收藏夹
Article Pharmacology & Pharmacy

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

K. K. Filipski et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)

添加到收藏夹
Review Oncology

Cholangiocarcinoma

Stefania Mosconi et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)

添加到收藏夹
Review Public, Environmental & Occupational Health

Cisplatin Overdose Toxicities and Management

Roger Y. Tsang et al.

DRUG SAFETY (2009)

添加到收藏夹
Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

添加到收藏夹
Article Physiology

The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity

Navjotsingh Pabla et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)

添加到收藏夹
Review Oncology

A History of Cancer Chemotherapy

Vincent T. DeVita et al.

CANCER RESEARCH (2008)

添加到收藏夹
Article Oncology

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

Elizabeth M. Swisher et al.

CANCER RESEARCH (2008)

添加到收藏夹
Article Oncology

Interaction of cisplatin with the human organic cation transporter 2

Kelly K. Filipski et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹
Article Oncology

Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma

Maryam Fouladi et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹
Article Chemistry, Multidisciplinary

A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes

Matthias Ober et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)

添加到收藏夹
Article Multidisciplinary Sciences

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Wataru Sakai et al.

NATURE (2008)

添加到收藏夹
Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹
Article Biochemistry & Molecular Biology

Transcriptional activation of caspase-6 and-7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity

C. Yang et al.

CELL DEATH AND DIFFERENTIATION (2008)

添加到收藏夹
Review Medicine, General & Internal

Cisplatin nephrotoxicity: A review

Xin Yao et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)

添加到收藏夹
Review Oncology

The resurgence of platinum-based cancer chemotherapy

Lloyd Kelland

NATURE REVIEWS CANCER (2007)

添加到收藏夹
Article Urology & Nephrology

Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells

B. Zhang et al.

KIDNEY INTERNATIONAL (2007)

添加到收藏夹
Article Oncology

Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma

Jun Yong Park et al.

CANCER (2007)

添加到收藏夹
Article Audiology & Speech-Language Pathology

Prevention of noise- and drug-induced hearing loss with D-methionine

Kathleen C. M. Campbell et al.

HEARING RESEARCH (2007)

添加到收藏夹
Article Pharmacology & Pharmacy

Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)

Atsushi Yonezawa et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)

添加到收藏夹
Article Oncology

Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis

Zejia Yang et al.

CLINICAL CANCER RESEARCH (2006)

添加到收藏夹
Review Cell Biology

Functions of human replication protein A (RPA): From DNA replication to DNA damage and stress responses

Yue Zou et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2006)

添加到收藏夹
Article Oncology

Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption

EA Neuwelt et al.

PEDIATRIC BLOOD & CANCER (2006)

添加到收藏夹
Review Oncology

Role of copper transporters in the uptake and efflux of platinum containing drugs

R Safaei

CANCER LETTERS (2006)

添加到收藏夹
Article Urology & Nephrology

A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity

Manchang Liu et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)

添加到收藏夹
Review Gastroenterology & Hepatology

Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials

P. M. Lopez et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)

添加到收藏夹
Article Oncology

Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development

KRG Knight et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹
Review Medicine, General & Internal

Cholangiocarcinoma

SA Khan et al.

LANCET (2005)

添加到收藏夹
Article Urology & Nephrology

Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities

SS Byun et al.

BJU INTERNATIONAL (2005)

添加到收藏夹
Article Multidisciplinary Sciences

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

H Farmer et al.

NATURE (2005)

添加到收藏夹
Article Oncology

Risk-adapted treatment for childhood hepatoblastoma:: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2

G Perilongo et al.

EUROPEAN JOURNAL OF CANCER (2004)

添加到收藏夹
Article Pharmacology & Pharmacy

Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells

GL Beretta et al.

BIOCHEMICAL PHARMACOLOGY (2004)

添加到收藏夹
Review Gastroenterology & Hepatology

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

JM Llovet et al.

HEPATOLOGY (2003)

添加到收藏夹
Article Urology & Nephrology

Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death

K Tsuruya et al.

KIDNEY INTERNATIONAL (2003)

添加到收藏夹
Article Oncology

Adult type vs. childhood hepatocellular carcinoma - Are they the same or different lesions? Biology, natural history, prognosis, and treatment

P Czauderna

MEDICAL AND PEDIATRIC ONCOLOGY (2002)

添加到收藏夹
Article Multidisciplinary Sciences

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

S Ishida et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

添加到收藏夹
Article Medicine, Research & Experimental

TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity

G Ramesh et al.

JOURNAL OF CLINICAL INVESTIGATION (2002)

添加到收藏夹
Article Oncology

Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology Group

P Czauderna et al.

JOURNAL OF CLINICAL ONCOLOGY (2002)

添加到收藏夹
Article Radiology, Nuclear Medicine & Medical Imaging

Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion

K Kamada et al.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2001)

添加到收藏夹
Article Oncology

Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the international society of pediatric oncology

J Pritchard et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.